Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

ABSTRACT:

Background

Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement of concentrations of active tamoxifen metabolites in serum may be a more biological plausible and robust approach. We have investigated the association between CYP2D6 genotypes, serum concentrations of active tamoxifen metabolites, and long-term outcome in tamoxifen treated breast cancer patients.

Methods

From an original observational study comprising 817 breast cancer patients, 99 women with operable breast cancer were retrospectively included in the present study. This cohort of patients were adjuvantly treated with tamoxifen, had provided serum samples s

SUBMITTER: Helland T 

PROVIDER: S-EPMC5706168 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature